Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 28.9× earnings vs its 29.3× historical median P/E.
Fair value ≈ $16.70 · price $16.45 today
Fair value · 1% below
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Barclays believes the recent selloff in European consumer staples has been driven more by valuation compression than earnings deterioration, creating attractive opportunities as earnings downgrades ease and consumer demand shows signs of stabilization.
The broker favors companies with resilient earnings and discounted valuations. L’Oréal stands out for its strong profit profile, premium positioning, and long-term exposure to structural beauty market growth. Danone is viewed as one of the clearest re-rating opportunities after a sharp valuation reset despite only modest earnings cuts. Unilever remains attractive thanks to resilient earnings expectations and its diversified global portfolio.
Barclays also highlights Carlsberg, whose share price decline appears disconnected from stable earnings estimates, and Pernod Ricard, where much of the negative outlook may already be priced in.
$LRLCY $UL $DANOY
Nestlé and Danone are facing renewed scrutiny over how they handled the recall of contaminated infant formula, following investigations by public broadcasters in France, Belgium, and Switzerland.
The reports allege that Nestlé delayed notifying European authorities about the presence of cereulide, a toxin that can cause vomiting and diarrhea and poses heightened risks for infants. The contamination was linked to an ingredient supplied by China’s CABIO Biotech and used in products from multiple manufacturers, including Nestlé, Danone, and Lactalis.
According to the investigation, trace levels of the toxin were detected as early as November, but public recalls were only initiated in January, raising questions about whether affected products remained in distribution channels or households without timely warnings. The reports also suggested that some withdrawals may have been carried out quietly in certain markets before official recalls were issued.
$NSRGY $DANOY
PickAlpha Midday:
Nestlé is weighing another step back from ice cream as new CEO Philipp Navratil reviews the portfolio — including potentially trimming its stake in Froneri (the JV housing brands like Häagen-Dazs/Mövenpick) and/or folding remaining wholly-owned local ice cream ops into Froneri. The backdrop is simple: Nestlé stock is near an 8-year low (down ~40% from its 2022 peak), while key peers have meaningfully outperformed — so the market is forcing “simplify + sharpen capital allocation” decisions.
Tickers: $NSRGY $UL $DANOY
Our view is this is a classic self-help setup: exit/monetize lower-conviction assets to decomplexify and potentially fund deleveraging/buybacks. If Nestlé can show proceeds are real and reallocated into faster-growth/higher-return categories, the “discount to peers” narrative can start to close; if it’s just shuffling minority stakes without a broader margin/growth reset, it won’t move the needle.
Did you have see that all the game player in the food industry buy a microbiome company the last in date it’s Danone : https://www.danone.com/newsroom/press-releases/acquisition-of-the-akkermansia-company.html $MCRB $DANOY $NSRGY $UL
$DANOY Danone to acquire majority stake in Kate Farms
Danone announced that it has entered into a definitive agreement to acquire a majority stake in Kate Farms, a U.S. business offering a wide array of plant-based, organic nutrition products for both medical and everyday needs. Kate Farms' complementary products will enhance Danone's specialized nutrition offerings, Danone said in a statement.
Following the closing of the transaction, Kate Farms' CEO, Brett Matthews, will serve as Chairman and CEO of Danone's North American Medical Nutrition business. Kate Farms' senior management will retain a minority stake in the combined business. The transaction remains subject to customary closing conditions, including regulatory approval.
$DANOY earnings drop incoming 👀 Street's buzzing about this under-the-radar retail play. Will numbers match the whispers? Time to stalk those financials – could be a sneaky volatility window. Coffee-charting mode activated ☕ (No position, just watching heat)
$OTLY Yesterday I was visiting a friend who made me a cappuccino of the $DANOY Alpro branded barista oat milk. I can honestly say: it was disgusting, it tastes totally different than the Oatly barista version, in a bad way. It tastes more like real milk.
In order to be not biased I also tasted the pure Alpro oat milk. Well my verdict hasn't changed.
I suggested him to try Oatly :P
$LWAY $DANOY Lifeway Foods confirms $27.00 per share buyout proposal from Danone
Lifeway Foods (LWAY) confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America (DANOY) to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed with the U.S. SEC disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.
On November 5, Lifeway announced that its Board of Directors had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the company and its shareholders and other stakeholders. Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the company and its shareholders and other stakeholders.
